The stock has a beta value of 0.62. The business's revenue for the quarter was down 4.9% on a year-over-year basis.
Endo International plc (ENDP)'s current session activity disclosed discouraging signal for active traders. During the same period previous year, the company earned $0.86 earnings per share. Wall Street analysts covering the stock are projecting that the stock will reach $14.71 within the next 52-weeks.
Leerink Swann maintained Endo International plc - Ordinary Shares (NASDAQ:ENDP) on Tuesday, August 11 with "Outperform" rating. The consensus mean EPS for the current quarter is at $0.73 derived from a total of 19 estimates from the analysts who have weighed in on projected earnings. The Return on Investment (ROI) ratio of Endo International plc (ENDP) is -25.3 percent. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. Schneider Capital Management Corp now owns 642,311 shares of the company's stock valued at $7,168,000 after buying an additional 83,100 shares in the last quarter. The company had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the company. Canaccord Genuity set a $12.00 price objective on shares of Endo International PLC and gave the company a hold rating in a research report on Thursday, June 8th. Oppenheimer Holdings, Inc. reissued a "hold" rating on shares of Endo International PLC in a research note on Thursday, June 8th. Deutsche Bank AG downgraded their price objective on Endo International from $18.00 to $15.00 and fixed a "buy" recommendation on the share in a study note published on Fri, Jul 7th. Finally, Vetr upgraded Endo International PLC from a "hold" rating to a "buy" rating and set a $11.34 price target on the stock in a research report on Tuesday, May 9th. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. If you are accessing this news story on another website, it was illegally copied and republished in violation of U.S. and worldwide copyright legislation.
Shares of Endo are down almost 3% to $9.00 in after-hours trading Monday.
Analysts look for public financial statements, listen in on conference calls and talk to managers and customers of a company in order to reach an opinion and communicate the value of a stock. Financial Svcs has invested 0% in Endo International plc - Ordinary Shares (NASDAQ:ENDP).
Sony Xperia XZ1 spotted on GFX Bench
The XZ1 and XZ1 Compact smartphones will come along with high-end specs, while the X1 variant would be more of a mid-range option. Furthermore, the phone sports a 5.1 Inch full HD display with 1080 pixels of screen resolution.
Advanced Micro Devices, Inc
Following the completion of the transaction, the insider now directly owns 19,808 shares in the company, valued at $217,491.84. Intellectus Partners LLC purchased a new stake in Advanced Micro Devices during the first quarter valued at about $116,000.
MyoKardia, Inc. (NASDAQ:MYOK) Stock Rating Upgraded by TheStreet
Finally, Cowen and Company upped their price target on MyoKardia from $28.00 to $56.00 in a research report on Monday. TheStreet raised shares of MyoKardia from a d+ rating to a c rating in a research note on Thursday, July 6th.
Endo International plc has a consensus hold rating from 20 Wall Street analysts, and the number of shares now sold short amount to at least 8.77% of shares outstanding. Gamco Investors INC. ET AL raised its stake in Endo International PLC by 5.6% in the second quarter. Comerica Bank raised its stake in Endo International PLC by 1.2% in the second quarter. Now we take an assessment of last twelve months period, where stock moved lower with performance of -48.48%. TPG Group Holdings (SBS) Advisors Inc is the second biggest holder with 22 million shares now valued at 598.11 million whilst Vanguard Group Inc has 16 million shares valued at 183.94 million.
Endo International PLC (NASDAQ:ENDP) traded down 7.09% on Tuesday, hitting $8.65. The stock's market cap is $1.93 billion.
Analysts on average have given a price target of $14.71 to Endo International plc (ENDP) stock.
Endo International plc (ENDP) stock price fell -45.58 percent over the past one year, while decreased -21.35 percent during the past 6 months.
The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.